NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-07-23
Reading SRTA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity with a medium confidence level. The current thesis state is intact, supported by recent positive momentum despite mixed financial results.
The market appears to price in a low level of execution quality, indicating some fragility. Valuation is considered cheap compared to peers, with an expectations gap suggesting that the market is not overly optimistic.
Management is on track to achieve revenue guidance for 2026, but adjusted EBITDA and free cash flow targets are mixed. Near-term risks are elevated, especially given the company's recent earnings miss.
The thesis hinges on the performance of sector bellwethers like HCA, THC, and DVA. If these companies continue to perform well, it could support SRTA's growth; however, any negative guidance from them could adversely affect SRTA.
Overall, SRTA's outlook remains cautious but with potential for growth depending on sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting or exceeding this number shows progress toward the 2026 revenue target of $260-275M.
Confirms:Q2 revenue reported at or above $67.4M.
Disproves:Q2 revenue reported below $67.4M.
Why it matters: This date is important for checking financial performance and future plans.
Confirms one read:Earnings report shows strong results and raises guidance.
Confirms the other:Earnings report shows weak results and lowers guidance.
Why it matters: High revenue growth shows strong demand. It also means good execution of growth plans.
Confirms:Q2 revenue growth is over 80% compared to last year. This shows strong performance.
Disproves:Q2 revenue growth is below 70% compared to last year. This suggests demand is weakening.
Why it matters: If companies like Lilly or Johnson & Johnson do well, it helps Strata.
Confirms:Peer companies report strong revenue growth or improved outlooks.
Disproves:Peers are seeing lower revenues or bad outlooks.
Why it matters: This update will show if Strata can meet its cash flow target for 2026.
Confirms one read:Management raises free cash flow guidance to $22M or higher.
Confirms the other:Management lowers free cash flow guidance below $15M.
Why it matters: A drop could signal a slowdown in the healthcare sector, impacting Strata's performance.
Confirms:Sector revenue growth reported below its median.
Disproves:Sector revenue growth remains above its median.
Why it matters: Health Care sector growth is slowing. If revenue growth re-accelerates, it could help Strata's outlook.
Confirms:Health Care sector revenue growth is speeding up again. It is moving toward 10% or higher.
Disproves:Sector revenue growth is slowing down. It is now below 10%.
Why it matters: This cash flow is important for funding growth and operations, showing financial strength.
Confirms:Free cash flow reported in the range of $15-22M.
Disproves:Free cash flow reported below $15M.
Why it matters: Achieving this range is key for financial health and aligns with management's goals.
Confirms:Adjusted EBITDA was between $29M and $33M.
Disproves:Adjusted EBITDA was under $29M.
Why it matters: Reaching this target means progress toward the yearly EBITDA goal. It also shows better efficiency.
Confirms:Adjusted EBITDA for Q2 hits or exceeds $7 million.
Disproves:Adjusted EBITDA for Q2 falls below $6 million.
Why it matters: Strong cash flow means good financial health. It shows the ability to fund growth projects.
Confirms:Operating cash flow for Q2 exceeds $4 million.
Disproves:Operating cash flow for Q2 is below $3 million.
Why it matters: New acquisitions can boost growth. They can also expand service offerings and support long-term plans.
Confirms:Announcement of at least one new acquisition target or deal closure by Q3.
Disproves:No news on M&A activity by Q3. This shows the growth strategy may be stalled.
